(1) | For purposes of calculating the filing fee pursuant to Rule 0-11(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Transaction Valuation was calculated by adding (i) the product of (A) 30,358,385 shares, which is the total number of shares of common stock of Satsuma Pharmaceuticals, Inc. outstanding (“Shares”) not beneficially owned by SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (“SNBL”) (calculated as the difference between 33,152,498, the total number of outstanding Shares, and 2,794,113, the number of Shares beneficially owned by SNBL as of April 14, 2023) and (B) $0.91, which is the per Share tender offer price, and (ii) the product of (A) 242,284, which is the number of Shares issuable upon the exercise of vested “in-the-money” options to purchase the Shares, and (B) $0.01, which is the difference between $0.91, which is the per Share tender offer price, and $0.90, which is the weighted average per share exercise price of such options. The calculation of the Transaction Valuation is based on information provided by Satsuma Pharmaceutical, Inc. as of April 14, 2023, the most recent practicable date. |